Amyloid‐related imaging abnormalities from trials of solanezumab for Alzheimer's disease
Christopher Carlson(Eli Lilly (United States)), Jerome Barakos(Sutter Health), Eric Siemers(Eli Lilly (United States)), Joonmi Oh(Biogen (United States)), Roza Hayduk(IQVIA (United States)), Ann Marie Hake(Eli Lilly (United States)), Michael Case(Eli Lilly (United States)), Joyce Suhy(BioClinica (United States))
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
January 1, 2016
Cited by 65
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k